Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica - Sorbonne Université
Journal Articles Multiple Sclerosis Journal Year : 2021

Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica

Elisabeth Maillart
Xavier Moisset
Jean Pelletier
Kevin Bigaut
  • Function : Author
Laurent Kremer
  • Function : Author
Aude Maurousset
  • Function : Author
Vito a G Ricigliano
  • Function : Author

Abstract

Introduction: Recent studies suggested that anti-CD20 and fingolimod may be associated with lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination. We evaluated if COVID-19 occurred despite vaccination among patients with multiple sclerosis (MS) and neuromyelitis optica (NMO), using the COVISEP registry. Case series: We report 18 cases of COVID-19 after two doses of BNT162b2-vaccination, 13 of which treated with anti-CD20 and four with fingolimod. COVID-19 severity was mild. Discussion: These results reinforce the recommendation for a third COVID-19 vaccine dose among anti-CD20 treated patients, and stress the need for a prospective clinical and biological study on COVID-19 vaccine efficacy among MS and NMO patients.
Fichier principal
Vignette du fichier
Januel et al. - 2021 - Post-vaccine COVID-19 in patients with multiple sc.pdf (829.9 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03526127 , version 1 (14-01-2022)

Identifiers

Cite

Edouard Januel, Jérôme de Seze, Patrick Vermersch, Elisabeth Maillart, Bertrand Bourre, et al.. Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. Multiple Sclerosis Journal, 2021, pp.135245852110497. ⟨10.1177/13524585211049737⟩. ⟨hal-03526127⟩
185 View
96 Download

Altmetric

Share

More